display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - NA - all populationmML - NA - PDL1 positivemML - L1 - all populationmML - L1 - BRAF mutantmML - L1 - BRAF wildmML - L2 - all populationmML - L2 - BRAF mutant
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone E1609 ... MDX010 Ipi vs gp100
Ipilimumab (10 mg/kg) EORTC 18071 E1609 ... Ascierto ... CA184-004
ipilimumab plus gp100 MDX010 Ipi plus gp100 vs gp100 MDX010 Ipi plus gp100 vs Ipi ...
ipilimumab plus SoC CA184-024
tremelimumab A3671009
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib IMspire-170
atezolizumab plus SoC IMspire-150 ...
nivolumab based treatment
nivolumab alone CheckMate 238 IMMUNED ... CheckMate 067 ... CheckMate 066 CheckMate 037
nivolumab followed by ipilimumab CheckMate 064
pembrolizumab based treatment
pembrolizumab alone KEYNOTE 054 ... KEYNOTE 054 ...
pembrolizumab (10mg/kg) KEYNOTE-006 ... KEYNOTE-002 ...
pembrolizumab (10mg/kg) 2 weeks KEYNOTE-006 ...
pembrolizumab (2mg/kg) KEYNOTE-002 ...
pembrolizumab plus SoC KEYNOTE-022
Immune checkpoint association
nivolumab plus ipilimumab IMMUNED ... IMMUNED ... CheckMate 915 CheckMate 067 ... CheckMate 067 ... CheckMate 069 ... CheckMate 069 ... CheckMate 069 ...
relatlimab plus nivolumab RELATIVITY-047

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons